Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

[1]  U. Kopylov,et al.  Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti‐tumour necrosis factor , 2018, Alimentary pharmacology & therapeutics.

[2]  A. Amiot,et al.  One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study , 2017, Alimentary pharmacology & therapeutics.

[3]  T. Wyant,et al.  A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab , 2017, Clinical Pharmacokinetics.

[4]  J. Burisch,et al.  Systematic review with meta‐analysis: proximal disease extension in limited ulcerative colitis , 2017, Alimentary pharmacology & therapeutics.

[5]  J. Ludvigsson,et al.  Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) , 2017, Scandinavian journal of gastroenterology.

[6]  S. Vermeire,et al.  Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  J. Gisbert,et al.  Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation , 2017, Digestive Diseases and Sciences.

[8]  J. Hampe,et al.  Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study , 2016, Alimentary pharmacology & therapeutics.

[9]  John T. Chang,et al.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, The American Journal of Gastroenterology.

[10]  E. Seidman,et al.  Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease , 2016, Therapeutic advances in gastroenterology.

[11]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[12]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[13]  L. Peyrin-Biroulet,et al.  An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis , 2014, Gut.

[14]  C. Siegel,et al.  Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD , 2014, Gut.

[15]  D. McGovern,et al.  Towards personalized care in IBD , 2014, Nature Reviews Gastroenterology &Hepatology.

[16]  P. Rutgeerts,et al.  Targeting TNF-α for the treatment of inflammatory bowel disease , 2014, Expert opinion on biological therapy.

[17]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[18]  A. Kornbluth,et al.  Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[20]  K. Isaacs.  How Rapidly Should Remission Be Achieved? , 2010, Digestive Diseases.

[21]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[22]  Abhijeet Yadav,et al.  Variations in Health Insurance Policies Regarding Biologic Therapy Use in Inflammatory Bowel Disease. , 2017, Inflammatory bowel diseases.

[23]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.